相关论文: Explainable Deep Radiogenomic Molecular Imaging fo…

Glioblastoma, an aggressive brain cancer, is amongst the most lethal of all cancers. Expression of the O6-methylguanine-DNA-methyltransferase (MGMT) gene in glioblastoma tumor tissue is of clinical importance as it has a significant effect…

The presence of MGMT promoter methylation significantly affects how well chemotherapy works for patients with Glioblastoma Multiforme (GBM). Currently, confirmation of MGMT promoter methylation relies on invasive brain tumor tissue…

Background and aim: This study aimed to predict methylation status of the O-6 methyl guanine-DNA methyl transferase (MGMT) gene promoter status by using MRI radiomics features, as well as univariate and multivariate analysis. Material and…

The number of studies on deep learning for medical diagnosis is expanding, and these systems are often claimed to outperform clinicians. However, only a few systems have shown medical efficacy. From this perspective, we examine a wide range…

In this paper we propose a method for predicting the status of MGMT promoter methylation in high-grade gliomas. From the available MR images, we segment the tumor using deep convolutional neural networks and extract both radiomic features…

Glioblastoma is a common brain malignancy that tends to occur in older adults and is almost always lethal. The effectiveness of chemotherapy, being the standard treatment for most cancer types, can be improved if a particular genetic…

Non-invasive inference of molecular tumor characteristics from medical imaging is a central goal of radiogenomics, particularly in glioblastoma (GBM), where O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation carries…

Glioblastoma Multiforme (GBM) is a malignant brain cancer forming around 48% of al brain and Central Nervous System (CNS) cancers. It is estimated that annually over 13,000 deaths occur in the US due to GBM, making it crucial to have early…

GBM is a highly aggressive primary malignancy in adults, necessitating personalized therapeutic strategies due to its inherent molecular heterogeneity. MGMT promoter methylation is a pivotal prognostic biomarker for anticipating response to…

Brain tumors pose significant health challenges worldwide, with glioblastoma being one of the most aggressive forms. Accurate determination of the O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status is crucial for…

Glioblastoma Multiforme (GBM) is an aggressive form of malignant brain tumor with a generally poor prognosis. Treatment usually includes a mix of surgical resection, radiation therapy, and akylating chemotherapy but, even with these…

Glioblastomas, constituting over 50% of malignant brain tumors, are highly aggressive brain tumors that pose substantial treatment challenges due to their rapid progression and resistance to standard therapies. The methylation status of the…

Radiomic models have been shown to outperform clinical data for outcome prediction in glioblastoma (GBM). However, clinical implementation is limited by lack of parameters standardization. We aimed to compare nine machine learning…

The RSNA-MICCAI brain tumor radiogenomic classification challenge aimed to predict MGMT biomarker status in glioblastoma through binary classification on Multi parameter mpMRI scans: T1w, T1wCE, T2w and FLAIR. The dataset is splitted into…

Glioblastomas are the most common malignant brain tumors in adults. Approximately 200000 people die each year from Glioblastoma in the world. Glioblastoma patients have a median survival of 12 months with optimal therapy and about 4 months…

Glioblastoma (GBM) is an aggressive brain tumor in which IDH mutation status is a key prognostic biomarker, but traditional testing requires invasive biopsies, emphasizing the need for non-invasive approaches. In this multi-center study, we…

The aim of the systematic review was to assess recently published studies on diagnostic test accuracy of glioblastoma treatment response monitoring biomarkers in adults, developed through machine learning (ML). Articles were searched for…

Glioblastoma is the most malignant type of central nervous system tumor with GBM subtypes cleaved based on molecular level gene alterations. These alterations are also happened to affect the histology. Thus, it can cause visible changes in…

Objectives: Glioblastomas are the most aggressive brain and central nervous system (CNS) tumors with poor prognosis in adults. The purpose of this study is to develop a machine-learning based classification method using radio-mic features…

Background: Radiogenomics allows identification of radiological biomarkers for genomic phenotypes. In glioblastoma, these biomarkers could potentially complement patient stratification strategies. We aim to develop and analytically validate…